Keyvenb

Human Hepatitis B Immunoglobulin, the active ingredient in Keyvenb, is an immunoglobulin presented as a sterile intravenous solution for IV use. It provides passive immunity to prevent hepatitis B virus infection after exposure and to protect newborns of hepatitis B surface antigen‑positive mothers.

GNH USA supplies Keyvenb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Keyvenb, a human hepatitis B immunoglobulin, is used in the antiviral pathway to provide passive protection against hepatitis B virus. - Post‑exposure prophylaxis: prevents hepatitis B infection after known exposure to HBV. - Neonatal prophylaxis: protects newborns of HBsAg‑positive mothers by supplying anti‑HBs antibodies. - Immunoprophylaxis for at‑risk individuals: supplies passive immunity to persons lacking adequate hepatitis B immunity.

Keyvenb may be associated with infusion‑related reactions and immunoglobulin‑related adverse events.

Common Side Effects: - Fever - Chills - Headache - Nausea - Injection site reactions - Fatigue

Serious or Rare Side Effects: - Anaphylaxis - Severe hypotension - Renal dysfunction - Thrombotic events - Serum sickness - Hemolysis

Before administering Keyvenb, clinicians should observe several precautionary measures. - Screen for HBV status: confirm indication and need for passive immunization. - Assess for hypersensitivity: avoid in patients with known allergy to human immunoglobulin or IgA deficiency with anti‑IgA antibodies. - Monitor vital signs: observe for infusion reactions during and after administration. - Use aseptic technique: ensure sterile preparation and IV administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Keyvenb can interact with other medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Concurrent immunosuppressive monoclonal antibodies: may reduce the effectiveness of passive antibodies. - Live vaccines: may interfere with vaccine response and increase risk of adverse events. - Co‑administration with other high‑dose IVIG products: increases risk of hyperviscosity.

Moderate Interactions (Monitor Closely): - Anticoagulants: volume load may enhance bleeding tendency; monitor coagulation parameters. - Renally impairing drugs: monitor renal function as immunoglobulin load can affect kidneys.